Abstract

The aim of the present study was to determine the expression of plasminogen activator inhibitor‑1 (PAI‑1) and microRNA (miR)‑30b in the blood of patients with acute myocardial ischemia (AMI) and in the blood and myocardial tissue of mice with AMI. In addition, the present study aimed to identify the mechanism of action of miR‑30b in AMI. A total of 36 patients with AMI were included in the present study and 28 healthy subjects were included as a control. Peripheral blood was collected from all subjects. For animal experiments, mice in the AMI group received an intraperitoneal injection of pituitrin (20 U/kg), whereas mice in the negative control group received an intraperitoneal injection of the same volume of saline. Blood and myocardial tissue was collected from all mice for analysis. Reverse transcription‑quantitative polymerase chain reaction was performed to determine the expression of PAI‑1 mRNA and miR‑30b in the serum and myocardial tissue. An enzyme‑linked immunosorbent assay was performed to measure the expression of PAI‑1 protein in the serum of humans and mice, whereas western blotting was performed to determine the expression of PAI‑1 protein in mouse myocardial tissue. Catalase, glutathione peroxidase and superoxide dismutase activity was measured using an automatic biochemical analyzer. A dual luciferase assay was performed to identify the interactions between PAI‑1 mRNA and miR‑30b. The results indicated that patients with AMI have higher PAI‑1 levels and lower miR‑30b expression in the peripheral blood compared with healthy subjects. AMI damaged the myocardium tissue of mice and reduced catalase, glutathione peroxidase and superoxide dismutase activity. Mice that have undergone AMI exhibit increased PAI‑1 levels but decreased miR‑30b expression in the peripheral blood and myocardial tissues. It was also demonstrated that miR‑30b is able to bind to the